多种心力强化类固醇对β-粉样蛋白前体蛋白水平的影响
Irina Yu Petrushanko1, Denis R Lisitskii1, Maria A Strelkova1
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
Frontiers in pharmacology
|December 29, 2025
概括
内源性心力性类固醇 (CTS) 调节大脑中的粉样蛋白前体蛋白 (APP) 水平. 不同的CTS对APP的影响不同,影响其与β-粉样蛋白 (Aβ42) 的相互作用,并可能维持大脑平衡.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 内源性心性类固醇 (CTS) 是大脑组织中发现的Na,K-ATPase的配体.
- Na,K-ATPase是CTS和β-粉样蛋白 (Aβ42) 的目标.
- 之前的研究表明,奥阿巴因与Na,K-ATPase结合可以阻止Aβ42诱导的Src激酶激活,并改变粉样蛋白前体蛋白 (APP) 水平.
研究的目的:
- 为了研究马里诺布法宁,布法林和迪戈辛对人类神经母细胞瘤细胞APP水平的影响.
- 为了确定CTS诱导的APP变化是否依赖于Aβ42和Src激酶.
- 阐明CTS-Na,K-ATPase-Aβ42相互作用的分子机制.
主要方法:
- 细胞培养 (人类神经母细胞瘤SH-SY5Y细胞).
- 用各种CTS (ouabain,marinobufagenin,bufalin,digoxin) 和Aβ42.2进行治疗
- 对APP水平的测量.
- 对Src酶激活的评估.
- 对CTS-Na,K-ATPase-Aβ42相互作用的分子建模.
主要成果:
- 布法林和狄戈辛增加了APP水平,而不依赖于Aβ42.
- 马里诺布法宁放大了Aβ42诱导的APP增加,并激活了Src酶.
- 布法林和狄戈辛在与Aβ42结合时没有进一步提高APP;Src酶没有被激活.
- CTS没有导致神经瘤中APP的积累;ouabain,marinobufagenin和digoxin减少了Aβ42诱导的神经瘤中APP的增加.
- 分子建模表明,CTS与Na,K-ATPase结合会改变它与Aβ42.2的相互作用.
结论:
- 内源性CTS在神经元细胞中差异调节APP水平.
- 由CTS引起的APP变化可以通过Src独立的路径发生.
- CTS调节了Na,K-ATPase和Aβ42.4之间的相互作用.
- 内源性CTS是维持大脑中APP和Aβ42之间的平衡的关键调节者.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Heart Failure Drugs: β-Blockers
727
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
727
Antihypertensive Drugs: Action of β1 Blockers
1.8K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K


